ORIGINAL ARTICLE

Systemic mastocytosis with associated clonal haematological non-mast cell lineage diseases: a histopathological challenge

H-P Horny, K Sotlar, W R Sperr, P Valent

Aims: Although systemic mastocytosis (SM) with an associated clonal haematological non-mast cell lineage disease (SM-AHNMD) is a major subtype of SM, little is known about its frequency among myelogenous neoplasms, and mastocytosis in particular, or about AHNMD subtype frequencies.

Methods: Approximately 19,500 routine bone marrow biopsies were evaluated. Immunostaining with antibodies against tryptase, KIT, and CD25 and molecular analysis for detection of C-KIT point mutations were performed in approximately 550/4100 myelogenous malignancies including mastocytosis, almost all subtypes of myelodysplastic syndrome (MDS), myelodysplastic/myeloproliferative syndrome (MDS/MPD), MPD, and acute myeloid leukaemia (AML).

Results: SM was rare—it was diagnosed in only 64 bone marrows (0.3%) and made up 1.5% of myelogenous tumours. SM-AHNMD was the second most frequent subtype (20). SM-AHNMD was never included in the clinical differential diagnoses and was confirmed histologically in most cases only after appropriate immunostaining. The abnormal mast cell phenotype was confirmed by immunohistochemical demonstration of tryptase and CD25 coexpression. The following associated haematological neoplasms were found: MDS/MPD, AML, MPS, MDS, plasma cell myeloma, and unclassifiable myelogenous malignancy. C-KIT point mutations were detected in 16 of 20 cases.

Conclusions: SM-AHNMD can be diagnosed histologically in bone marrow trephines only after immunostaining with antibodies against tryptase, KIT, and CD25. Eighteen of 20 AHNMDs were of myeloid origin. C-KIT point mutations were present in 16 of 20 cases. The prognostic relevance of detecting SM associated with another haematological neoplasm remains unclear, but mast cell resistance to most cytoreductive agents is of major importance for treatment planning.

METHODS

Approximately 19,500 routinely processed bone marrow biopsy specimens were investigated between January 2000 and October 2003 at the institute of pathology (reference centre for haematopathology) of the University of Lübeck, Lübeck, Germany. The tissues were fixed in 5% neutral formalin, mildly decalcified in edetic acid for six to eight hours, and embedded in paraffin wax. Conventional stains, such as Giemsa, Gomori’s silver impregnation, and naphthol AS-D chloroacetate esterase, were applied to all trephine specimens. In most myelogenous neoplasms (myelodysplastic and myeloproliferative syndromes and acute myeloid leukaemia), sections were immunostained using the avidin–biotin complex method with antibodies against various stem cell associated (CD34, CD38, and terminal deoxynucleotidyl...
Mastocytosis of SM-AHNMD type

RESULTS

Regarding the morphological evaluation of routinely processed bone marrow biopsy trephines, SM, irrespective of the subtype, comprised approximately 0.3% of all haematological diagnoses (approximately 19 500), and nearly 1.5% of all myelogenous neoplasms (approximately 4100). Within the spectrum of mastocytosis, SM-AHNMD was the second most frequent type with a total of 20 cases (indolent SM including bone marrow mastocytosis and smouldering mastocytosis, 35; aggressive SM, seven; mast cell leukaemia, two). The clinical records of the patients with SM-AHNMD never included a differential diagnosis of mastocytosis. The age of these patients ranged from 45 to 78 years with a median of 65 years. The male to female ratio was nearly 2 : 1. In most of the cases (18 of 20), the clinical picture resembled that of a myeloproliferative or myelodysplastic syndrome; only two patients were recorded to have a monoclonal gammapathy of undetermined significance.

In most of the cases, compact mast cell infiltrates were obscured by the associated haematological neoplasm (AHNMD) when only haematoxylin and eosin or Giemsa stained sections were investigated. Meticulous analysis of the whole biopsy specimen using high power magnification sometimes revealed a few small foci consisting of spindle shaped cells with intermingled macrophages and eosinophils, and a pronounced increase in reticulin fibres. It was easier to detect such infiltrates within sheets of relatively monotonous blast cells than in the much more heterogeneous myelodysplastic or myeloproliferative syndromes. In almost all cases (19 of 20), the bone marrow was extremely hypercellular, with subtotal depletion of fat cells and widely effaced normal microarchitecture. Depending on the AHNMD, the morphological picture was dominated by sheets of blast cells (in cases of AML; n = 4), an increased atypical and left shifted granulocytopenia and erythrocytopenia (in MDS; n = 2), increased numbers of pleomorphic often clustered megakaryocytes (in MDS; n = 3), a diffuse increase in immature myeloid and monocytoid cells (in MDS/MPS, usually chronic myelomonocytic leukaemia of type CMML1; n = 7), or focal accumulations of atypical plasma cells (in plasma cell myeloma; n = 2). In two cases, the AHNMD could not be classified on the basis of the histopathological aspect alone, but was found to fit best into the category of a MDS/MPS. The only case of SM-AHNMD with hypocellular marrow was that of an associated plasma cell myeloma, with only slight infiltration of the bone marrow and secondary light chain associated (AL) amyloidosis. Table 1 lists the definitive diagnoses of the AHNMDs.

Immunohistochemically, the demonstration of at least one compact dense mast cell infiltrate was very easy when antitryptase staining was applied (figs 1 and 2). The accumulations of tryptase expressing mast cells were sharply demarcated from the surrounding bone marrow. In almost all cases, more than 25% of the mast cells exhibited a spindle shaped morphology. The mast cells coexpressed KIT (CD117) and CD25, and CD117) antigens. Molecular biological studies were performed using peptide nucleic acid mediated polymerase chain reaction (PCR) clamping and Light Cycler hybridisation probes, as described previously. In selected cases, microdissected mast cells were investigated for the presence of C-KIT mutations, as also described previously. Diagnoses of haematological neoplasms including mastocytosis were established according to the WHO classification. The clinical records of the patients with SM-AHNMD were evaluated, in particular with respect to suspected mastocytosis.

Table 1: Systemic mastocytosis with an associated clonal haematological non-mast cell disease (SM-AHNMD): list of diagnoses of the AHNMDs and biological features of neoplastic cells

<table>
<thead>
<tr>
<th>AHNMD</th>
<th>No. of cases</th>
<th>C-KIT mutation (N)</th>
<th>CD25+</th>
</tr>
</thead>
<tbody>
<tr>
<td>MDS: RARS</td>
<td>1</td>
<td>D816V (1)</td>
<td>1/1</td>
</tr>
<tr>
<td>MDS: RAEB1</td>
<td>1</td>
<td>D816V (1)</td>
<td>1/1</td>
</tr>
<tr>
<td>MDS/MPS (CMML)</td>
<td>7</td>
<td>D816V (5)</td>
<td>7/7</td>
</tr>
<tr>
<td></td>
<td></td>
<td>D816Y (1)</td>
<td></td>
</tr>
<tr>
<td>MPS: PVR</td>
<td>1</td>
<td>wt (1)</td>
<td></td>
</tr>
<tr>
<td>MPS: CIM</td>
<td>2</td>
<td>D816V (2)</td>
<td>2/2</td>
</tr>
<tr>
<td>AML M1</td>
<td>1</td>
<td>No amplification</td>
<td>1/1</td>
</tr>
<tr>
<td>AML M2</td>
<td>2</td>
<td>D816V (2)</td>
<td>2/2</td>
</tr>
<tr>
<td>AML M4</td>
<td>1</td>
<td>wt (1)</td>
<td></td>
</tr>
<tr>
<td>Plasma cell myeloma</td>
<td>2</td>
<td>D816V (1)</td>
<td>2/2</td>
</tr>
<tr>
<td>NC (probably MDS/ MPS)</td>
<td>2</td>
<td>D816V (2)</td>
<td>2/2</td>
</tr>
<tr>
<td>Total</td>
<td>20</td>
<td>16</td>
<td>20</td>
</tr>
</tbody>
</table>

AML, acute myeloid leukaemia; CIM, chronic idiopathic myelofibrosis; CMML, chronic myelomonocytic leukaemia; D816V, Asp816→Val; D816Y, Asp816→Tyr; MPS, myelodysplastic/myeloproliferative syndrome; NC, not classifiable; PVR, polycythemia vera rubra; RAEB1, refractory anaemia with excess of blasts (5–10%); RARS, refractory anaemia with ringed sideroblasts; wt, wild-type.

in a specific anular pattern, but were also positive for CD25, thus exhibiting an abnormal immunophenotype. Not only the lesional mast cells within the compact infiltrates, but also the loosely scattered mast cells, coexpressed tryptase and CD25. One exceptional case with an associated CMML showed only loosely scattered spindle shaped mast cells, sometimes aggregated into small perivascular clusters. Compact mast cell infiltrates according to the major diagnostic criterion of the WHO classification were not detected. Nevertheless, because three minor criteria ("spindling", "expression of CD25", and "D816V point mutation") could be demonstrated, a diagnosis of SM-AHNMD was established. It is of interest that one case of SM with an associated AML exhibiting the t(8;21) translocation could not be diagnosed in the initial trephine biopsy. The second bone marrow biopsy removed after induction chemotherapy revealed disseminated compact infiltrates of atypical mast cells coexpressing tryptase and CD25 in a widely aplastic oedematous bone marrow. Re-evaluation of the initial tissue showed a slight increase of loosely scattered spindle shaped mast cells expressing tryptase and CD25, but compact infiltrates could not be detected. However, there was one paratrabecular small complex of about 10 mast cells reminiscent of a distorted compact infiltrate partly replaced by the AML blast cells. Because the point mutation D816V was detected in this initial trephine biopsy specimen, this case also fulfilled three minor diagnostic criteria, enabling the diagnosis of SM-AHNMD to be made. The plasma cell myelomas exhibited unusual features. One case was that of an extremely rare IgM/k plasma cell myeloma, one case showed only slight infiltration of the bone marrow by neoplastic plasma cells of IgG3, type associated with a generalised secondary AL amyloidosis, which involved the small bowel, leading to the initial presentation of an exudative enteropathy.

Molecular biological findings revealed the typical point mutation within the C-KIT protooncogene (D816V) in 14 of 20 cases, and uncommon point mutations (D816Y) in a further two cases associated with CMML and AMLM2. Three patients were found to exhibit the wild-type C-KIT alleles (SM associated with CMML, AMLM4, and polycythema vera) by peptide nucleic acid mediated PCR clamping. In one

www.jclinpath.com

Downloaded from http://jcp.bmj.com/ on April 4, 2017 - Published by group.bmj.com
of these three cases, microdissected mast cells were investigated but also exhibited the wild-type allele. In a final case, amplifiable DNA could not be extracted (association with AMLM1). With the exception of an associated AML with the t(8;21) translocation, other cytogenetic abnormalities of the AHNMDs were not recorded.

DISCUSSION

The main findings of this study can be summarised as follows:

- Among the four defined subtypes of SM, indolent SM was the most frequent (n = 35), with SM-AHNMD (n = 20) next in line, and therefore much more common than aggressive SM (n = 7) or the very rare true mast cell leukaemia (n = 2).
- Clinically, mastocytosis was never included in the differential diagnosis. Therefore, SM-AHNMD proved to be primarily a histological diagnosis that apparently depends on the experience of the haematopathologist, particularly his or her familiarity with mast cell proliferative disorders.
- The frequency distribution of the AHNMD shows a pronounced predominance of myelogenous neoplasms (18 of 20), in particular AML (n = 4) and MDS/MPS (n = 7).
- Sixteen of the 20 cases with SM-AHNMD showed a point mutation of the C-KIT protooncogene, mostly of the common type D816V (14 of 16).
- Mast cells of both the compact infiltrates and the diffuse (loosely scattered) compartments exhibited an abnormal immunophenotype, with coexpression of tryptase and CD25, which is never encountered in normal/reactive mast cells. These findings are of particular importance for the discrimination of mastocytosis from mast cell hyperplasia and for the diagnosis of indolent SM in patients with mastocytosis.
cutaneous mastocytosis lacking compact mast cell infiltrates within the bone marrow.

Very little is known about the frequency distribution of mastocytosis within the spectrum of suspected haematological disorders, and about the subtypes of the associated haematological malignancies in SM-AHNMD. We found that mastocytosis is a very rare disorder, amounting to only 0.3% of diagnoses established on bone marrow biopsies (nearly 19 500) evaluated by haematopathology (institute of pathology, University of Lübeck, Lübeck, Germany) within a period of about three years. Among the myelogenous tumours (approximately 4100), mastocytosis made up about 1.5% of all cases and thus belonged to the group of rare neoplasms. SM-AHNMD is a novel entity defined in the recent WHO classification of malignant tumours of the haemopoietic tissues and comprises all cases of SM with an associated non-mast cell lineage clonal haematological disease. As expected, myelogenous malignancies made up most of the AHNMDs (18 of 20), with a predominance of MDS/MPS (n = 7) and AML (n = 4), the former including a spectrum of myelogenous tumours, in particular CMMML, which were defined in the recent WHO classification of malignant haemopoietic tumours.

Our findings on the frequency distribution of AHNMDs are comparable to published data, which also reported a preponderance of myelogenous malignancies compared with overt lymphoproliferative disorders. The total number of published cases of SM-AML amounts to nearly 30 and covers the whole spectrum of subtypes according to the FAB classification, with a peak for AML types M2 and M5. Moreover, most subtypes of chronic myeloproliferative disorders have been described as AHNMDs, including essential thrombocythaemia. However, to the best of our knowledge, an association of SM with Philadelphia chromosome positive chronic myeloid leukaemia has not been reported. According to all published data, the most frequent myelogenous neoplasm associated with SM is CMMML, which is included in the group of MDS/MPS. According to our experience, the incidence of a diagnosis of SM-AHNMD should increase if appropriate immunostaining protocols are used. This is particularly important when dealing with very rare entities.

According to a previous report, the occurrence of mastocytosis in patients diagnosed with haematological malignancies is much more common in patients with mastocytosis than in patients with haematological malignancies. The most likely answer is that both haematological diseases evolve from an early uncommitted haemopoietic progenitor cell as a primary monoclonal disease, with further evolution into phenotypically different subclones. This hypothesis is the most likely in the most common forms of SM-AHNMD, namely those with associated myelogenous neoplasms. However, there is the possibility of the coincidental development of two distinct clonal haematological tumours. This concept would fit for the rare occurrence of SM associated with lymphoproliferative disorders/plasma cell dyscrasias. Interestingly, monoclonal gammopathy of uncertain significance is much more common in patients with mastocytosis than overt B cell neoplasms/plasma cell dyscrasias. Moreover, point mutations of C-KIT have been detected in circulating B cells.

Finally, is there any clinical relevance for the coincidental histomorphological detection of SM in the bone marrow of patients within the setting of another haematological malignancy? The clinical relevance of such histological, mostly unexpected, findings is largely unknown. It must be stated that as far as we know at this time, the “SM” in SM-AHNMD should be treated like pure SM and the “AHNMD” should usually be treated in the same manner as pure
Take home messages

- Systemic mastocytosis (SM) with an associated clonal haematological non-mast cell lineage disease SM-AHNMD can be diagnosed histologically in bone marrow trephines only after immunostaining with antibodies against tryptase, KIT, and CD25
- Most AHNMDs are of myeloid origin and C-KIT point mutations were present in 18 of the 20 cases
- The prognostic relevance of detecting SM associated with another haematological neoplasm remains unclear, but mast cell resistance to most cytoreductive agents is of major importance for treatment planning

AHNMD,23 However, the resistance of neoplastic mast cells to cytoreductive drugs has to be borne in mind. In this regard, it is also noteworthy that imatinib is unlikely to be an effective agent in such patients because the D816V mutation of C-KIT converts KIT to an imatinib resistant kinase receptor.24 This fact is underlined by our findings in a patient with AML type M2 with t(8;21) in whom treatment resulted in long standing complete haematological and cytogenetic remission of the AML but the disclosure and persistence of SM.14 In addition, a patient with AML associated with mast cell leukaemia was reported to achieve complete molecular remission of the AML soon after induction chemotherapy, whereas the mastocytosis persisted after standard chemotherapy and allogeneic stem cell transplantation.25

To summarise, SM-AHNMD is a primarily morphological diagnosis based on a thorough investigation of bone marrow trephine specimens including trypetase and CD25 immunohistochemistry. The most frequent AHNMDs are myelogenous neoplasms belonging to the group of myelodysplastic/myeloproliferative syndromes (CMML) and acute myeloid leukemias.

References

Systemic mastocytosis with associated clonal haematological non-mast cell lineage diseases: a histopathological challenge
H-P Horny, K Sotlar, W R Sperr and P Valent

doi: 10.1136/jcp.2003.014860

Updated information and services can be found at:
http://jcp.bmj.com/content/57/6/604

These include:

References
This article cites 20 articles, 5 of which you can access for free at:
http://jcp.bmj.com/content/57/6/604#BIBL

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections

- Immunology (including allergy) (1664)
- Dermatology (222)
- Clinical diagnostic tests (805)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/